AKBA at a glance
Akebia Therapeutics, Inc. (AKBA, SEC CIK 1517022) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on August 5, 2026, an 8-K current report on August 5, 2026 and Form 4 insider filings as recently as August 10, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Akebia Therapeutics, Inc. (AKBA) reported revenue of $236.2 million (up 47.5% from FY2024) and a net loss of $5.3 million. Diluted EPS was -$0.02.
- As of June 30, 2026, 30 institutional investment managers tracked by SignalX reported holding Akebia Therapeutics, Inc. (AKBA) shares worth $81.2 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Ostrowski Erik on June 29, 2026 of 56,019 shares at $1.11 per share.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $236.2M
- +47.5% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 30 funds
- $81.2M · +1 vs prior quarter
- Latest 8-K
- Aug 5, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Commercial portfolio: Vafseo launched January 2025; Auryxia reached loss of exclusivity March 2025
- Worst product outlook: Auryxia generic entered market after Teva ANDA approval on March 11, 2026
- R&D expenses $1.8B cumulatively through June 30, 2026
- Near-term headwinds: Auryxia generic competition and significant ongoing R&D expenditures
Risk Factors
- Continued losses and uncertain profitability from high R&D and commercialization costs
- Refinancing dependency for senior secured term loan, with principal payments otherwise starting January 1, 2027
- Funding runway of at least two years contingent on product, royalty, supply and license revenues
- Product approval and commercial viability risk despite two approved products, Auryxia and Vafseo
AI summary of the AKBA 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Second-quarter results for period ended June 30, 2026, with business highlights
- Press release furnished as Exhibit 99.1, containing the financial details investors need
Item 7.01: Regulation FD Disclosure
- VOICE trial interim analysis met predefined stopping criteria
- Vafseo demonstrated non-inferiority and superiority on the primary composite endpoint
Item 8.01: Other Events
- VOICE trial stopped early after 2,116 patients met prespecified non-inferiority and superiority criteria for Vafseo versus standard ESA
- Vafseo achieved win odds 1.16, 95% CI 1.06–1.28, p=0.0016, strengthening its dialysis anemia treatment profile
Item 5.07: Submission of Matters to a Vote of Security Holders
- Stockholders elected Adrian Adams, Michael Rogers and LeAnne M. Zumwalt as Class III directors through 2029
- Authorized capital increased from 375,000,000 to 525,000,000 shares
AI summaries of AKBA 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for AKBA
Don't miss the next AKBA filing
- Alerts as it files. A push when AKBA files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut AKBA, by share count.
- Ask anything. An AI agent that reads every AKBA filing and answers with sources.
AKBA alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Butler John P. | M | Aug 6, 2026 | 350,000 | - |
| Butler John P. | M | Aug 6, 2026 | 350,000 | $0.63 |
| Ostrowski Erik | Sell | Jun 29, 2026 | 56,019 | $1.11 |
| ZUMWALT LEANNE M | A | Jun 17, 2026 | 53,600 | - |
| ADAMS ADRIAN | A | Jun 17, 2026 | 53,600 | - |
| ZUMWALT LEANNE M | A | Jun 17, 2026 | 35,700 | - |
| ROGERS MICHAEL W | A | Jun 17, 2026 | 35,700 | - |
| Wolf Myles | A | Jun 17, 2026 | 53,600 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $160.2M | $236.2M |
| Operating Income | - | -$50.5M | $23.5M |
| Net Income | -$51.9M | -$69.4M | -$5.3M |
| Op. Margin | - | -31.5% | 9.9% |
| Net Margin | - | -43.3% | -2.3% |
| Balance Sheet | |||
| Total Assets | - | $220.7M | $376.6M |
| Equity | -$30.6M | -$49.2M | $32.6M |
| ROE | 169.8% | 141.1% | -16.4% |
| Per Share | |||
| EPS | $-0.28 | $-0.33 | $-0.02 |
| Cash Flow | |||
| Operating CF | - | -$40.7M | $68.0M |
| CapEx | $0 | $33K | $291K |
Source: XBRL data in Akebia Therapeutics, Inc. (AKBA)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate AKBA share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 30 | $81.2M |
| Q1 2026 | 29 | $95.6M |
| Q4 2025 | 25 | $125.9M |
| Q3 2025 | 26 | $220.3M |
| Q2 2025 | 27 | $259.3M |
| Q1 2025 | 24 | $81.1M |
| Q4 2024 | 20 | $50.4M |
| Q3 2024 | 16 | $13.5M |
- AQR Capital Management+7.36M (+411%)
- BlackRock+1.29M (+7%)
- Two Sigma Investments+1.14M (+88%)
- Millennium Management+811.9K (+34%)
- Ameriprise Financial+615.8K (+5926%)
- State Street Corp−6.22M (-54%)
- Bank of America Corp−2.30M (-83%)
- Citigroup−1.73M (-61%)
- Renaissance Technologies LLC−609.2K (-33%)
- Dimensional Fund Advisors−563.3K (-61%)
Source: 13F-HR filings on SEC EDGAR (aggregated from 197 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
AKBA filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Aug 10, 2026 | - | - | - |
| 8-K | Aug 5, 2026 | - | Analysis | - |
| 10-Q | Aug 5, 2026 | Jun 30, 2026 | Analysis | |
| 4 | Jul 1, 2026 | - | - | - |
| 8-K | Jun 30, 2026 | - | Analysis | - |
| 4 | Jun 22, 2026 | - | - | - |
| 4 | Jun 22, 2026 | - | - | - |
| 4 | Jun 22, 2026 | - | - | - |
| 4 | Jun 22, 2026 | - | - | - |
| 4 | Jun 22, 2026 | - | - | - |
| 8-K | Jun 22, 2026 | - | Analysis | - |
| 4 | Jun 22, 2026 | - | - | - |
| SC 13G | May 12, 2026 | - | - | |
| 8-K | May 7, 2026 | - | Analysis | |
| 10-Q | May 7, 2026 | Mar 31, 2026 | Analysis | |
| 4 | Apr 3, 2026 | - | - | - |
| 8-K | Apr 1, 2026 | - | - | - |
| 4 | Mar 5, 2026 | - | - | - |
| 10-K | Feb 26, 2026 | Dec 31, 2025 | - | |
| 8-K | Feb 26, 2026 | - | Analysis | - |
| SC 13G | Feb 9, 2026 | - | - | |
| 4 | Feb 4, 2026 | - | - | |
| 4 | Feb 4, 2026 | - | - | |
| 4 | Feb 4, 2026 | - | - | |
| 4 | Feb 4, 2026 | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
AKBA SEC filings: frequently asked questions
Which institutions hold AKBA stock?
As of June 30, 2026, the largest Akebia Therapeutics, Inc. (AKBA) holders among the 13F filers tracked by SignalX were BlackRock ($22.8 million), Vanguard Capital Management LLC ($12.9 million), AQR Capital Management ($10.4 million), State Street Corp ($6.1 million), Goldman Sachs Group ($4.2 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was AKBA's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Akebia Therapeutics, Inc. (AKBA) reported revenue of $236.2 million (up 47.5% from FY2024) and a net loss of $5.3 million. Diluted EPS was -$0.02. The figures come from the XBRL data in the 10-K.
What did AKBA report in its latest 8-K?
Akebia Therapeutics, Inc. (AKBA) filed an 8-K on August 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Second-quarter results for period ended June 30, 2026, with business highlights.
What are the latest AKBA SEC filings?
Akebia Therapeutics, Inc. (AKBA) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on August 5, 2026, an 8-K current report on August 5, 2026 and a Form 4 insider filing on August 10, 2026.
What is AKBA's SEC CIK number?
Akebia Therapeutics, Inc. (AKBA)'s SEC Central Index Key (CIK) is 1517022. EDGAR lists every AKBA filing under that number.
Ask anything about AKBA
The research agent reads AKBA's filings, financials, insider trades and 13F holders, then answers with sources.